HER-2/neu expression in germ cell tumours
暂无分享,去创建一个
K. Miller | L. Cheng | G. Vance | L. Baldridge | V. Thurston | S. Soule | L. Einhorn | L. R. Smith | Liang Cheng | K. Kirkpatrick | J. Gilbert
[1] D. Iannitti,et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. , 2001, Cancer investigation.
[2] K S Panageas,et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] T. Grogan,et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] I. Ellis,et al. Recommendations for HER2 testing in the UK , 2000, Journal of clinical pathology.
[5] L. Einhorn. Treatment of testicular cancer: a new and improved model. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[7] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.